A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
Completed · Phase 3 · NCT00891202
Conditions: Gaucher Disease, Type 1
At a glance
- Research payments reported, 2025
- $1,500
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Genzyme, a Sanofi Company
- Tested
- Eliglustat tartrate (drug), Placebo (drug)
- Dates
- Started 2009-11; completion 2016-01
- Results posted
- Yes
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
From ClinicalTrials.gov, last updated 2017-03-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $1,500 in research payments for this study in 2025 (3 payments).
Products named: Cerdelga
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.